3.48
0.10 (2.96%)
0.10 (2.96%)
Upgrade to Real-Time
Regular Market
Volume | 341,251 |
|
|||||
News | - | ||||||
Day High | 3.5801 | Low High |
|||||
Day Low | 3.36 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Mind Medicine MindMed Inc | MNMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.42 | 3.36 | 3.5801 | 3.38 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,104 | 341,251 | $ 3.51 | $ 1,198,645 | - | 2.12 - 22.20 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:06:07 | 100 | $ 3.48 | USD |
Mind Medicine MindMed Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 130.75M | 37.57M | 37.28M | $ - | $ - | - | -1.50 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | -8.68k | 17.80% |
Mind Medicine MindMed News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.42 | 3.62 | 3.09 | 3.38 | 488,130 | 0.06 | 1.75% |
1 Month | 2.60 | 3.77 | 2.531 | 3.28 | 624,687 | 0.88 | 33.85% |
3 Months | 2.57 | 3.77 | 2.12 | 2.87 | 595,255 | 0.91 | 35.41% |
6 Months | 10.50 | 19.95 | 2.12 | 12.10 | 4,733,239 | -7.02 | -66.86% |
1 Year | 16.5975 | 22.20 | 2.12 | 12.86 | 3,852,190 | -13.12 | -79.03% |
3 Years | 86.55 | 86.55 | 2.12 | 30.17 | 4,890,262 | -83.07 | -95.98% |
5 Years | 86.55 | 86.55 | 2.12 | 30.17 | 4,890,262 | -83.07 | -95.98% |
Mind Medicine MindMed Description
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies. |